CHICAGO, April 3, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today presented results from two preclinical studies on the development of Dock-and-Lock (DNL) derived novel therapeutic agents targeting solid tumors, including renal cell carcinomas (RCC).
